Zimlovisertib Explained

Drug Name:

Zimlovisertib

C:

18

H:

20

F:

1

N:

3

O:

4

Iupac Name:

1-(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-ylmethoxy]-7-methoxyisoquinoline-6-carboxamide| CAS_number = 1817626-54-2| CAS_supplemental = | DrugBank = DB15143| ChemSpiderID = 58805665| PubChem = 118414016| UNII = S3F315JJXI| ChEMBL = 4081711| smiles = CC[C@H]1[C@H](NC(=O)[C@H]1F)COC2=NC=CC3=CC(=C(C=C32)OC)C(=O)N| StdInChI = 1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)/t10-,13+,15-/m0/s1| StdInChIKey = JKDGKIBAOAFRPJ-ZBINZKHDSA-N}}Zimlovisertib (PF-06650833) is a drug which acts as a selective inhibitor of the enzyme Interleukin-1 receptor-associated kinase 4 (IRAK-4). It has antiinflammatory effects and has been trialed for various indications including hidradenitis suppurativa and treatment of COVID-19 infection, and while it has not been adopted into clinical use it continues to be used for research in this area.^{[1] [2] [3]}

See also

• Emavusertib

References

]

Notes and References

1. Zapata-Acevedo CA, Guevara-Vela JM, Popelier PL, Rocha-Rinza T . Binding Energy Partition of Promising IRAK-4 Inhibitor (Zimlovisertib) for the Treatment of COVID-19 Pneumonia . ChemPhysChem . 23 . 24 . e202200455 . December 2022 . 36044560 . 10.1002/cphc.202200455 . 9538207 .
2. Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B . Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa . NEJM Evidence . 3 . 3 . EVIDoa2300155 . March 2024 . 38335032 . 10.1056/EVIDoa2300155 .
3. Wright SW, Farley KA, Han S, Knafels JD, Lee KL . In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833) . ACS Medicinal Chemistry Letters . 15 . 4 . 540–545 . April 2024 . 38628800 . 10.1021/acsmedchemlett.4c00036 . 11017396 . April 11, 2025 .